References
- 1QuirozCGulyaniSRuiqianWBonaventuraJCutlerRPearsonVet alAdenosine receptors as markers of brain iron deficiency: implications for restless legs syndromeNeuropharmacology2016111160168doi: http://doi.org/10.1016/j.neuropharm.2016.09.00227600688
- 2ZhuXYLiuYZhangXJYangWHFengYOndoWGet alClinical characteristics of leg restlessness in Parkinson’s disease compared with idiopathic restless legs syndromeJ Neurol Sci2015357109114doi: http://doi.org/10.1016/j.jns.2015.07.00826189051
- 3MollerJCUngerMStiasny-KolsterKOertelWHRestless legs syndrome (RLS) and Parkinson’s disease (PD)-related disorders or different entities?J Neurol Sci2010289135137doi: http://doi.org/10.1016/j.jns.2009.08.03519755200
- 4DeCerceJSmithLFGonzalezWSussmanNMEffectiveness and tolerability of istradefylline for the treatment of restless legs syndrome: an exploratory study in five female patientsCurr Ther Res Clin Exp200768349359doi: http://doi.org/10.1016/j.curtheres.2007.11.00124692766
- 5MizunoYKondoKand the Japanese Istradefylline Study GroupAdenosine A2A receptor antagonist Istradefylline reduces daily OFF Time in Parkinson’s diseaseMov Disord201328113841doi: http://doi.org/10.1002/mds.2541823483627
- 6WaltersASLeBrocqCDharAHeningWRosenRAllenRPet alValidation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndromeSleep Med20034121132doi: http://doi.org/10.1016/S1389-9457(02)00258-714592342
- 7IranzoAComellaCLSantamariaJOertelWRestless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous systemMov Disord200722S424430.1doi: http://doi.org/10.1002/mds.2160017534950
- 8MarquesAFantiniMLMorandDPereiraBDerostPUllaMet alEmergence of restless legs syndrome after subthalamic stimulation in Parkinson’s disease: a dopaminergic overstimulation?Sleep Med201516583588doi: http://doi.org/10.1016/j.sleep.2014.11.02025881920